Pharmafile Logo

Ezulix Software Private Limited

Ezulix Software is one of the leading website & mobile Game app development Company located in London, UK. provides custom software development services worldwide. 9+ Years Exp. 250+ Global Clients. 24/7 Support.

This is a FREE LISTING on PMHUB

Below are full profiles from other companies in related areas

Genetic Digital

We guide healthcare and life sciences organisations through digital transformation. Simplifying the complex world of tech and marketing, we create impactful assets and strategies to drive long-term growth and positive…

View Profile

Nmblr

From day-one concept to launch and beyond, Nmblr is the strategy and collaboration platform that partners with biopharma teams.

View Profile

Company Details

71-75 Shelton Street, London, United Kingdom
+447956982975

 Latest Content from PMHub 

Pegasus Moves to Brighton

Press Releases | April 29, 2014 | Inizio

Top UK Healthcare Communications Consultancy Moves to Brighton

UX: Designing Human Experiences

Applying science to the creative process to improve lives

08 UX: Pushing the right buttons

Unlocking better outcomes in healthcare with UX

UX: Pushing the right buttons

Unlocking better outcomes in healthcare with UX

07 Good Pharma

Better for patients, better for business

05 Social Media: A Health Hazard?

The case to embrace going social

Creating a Lifeline to the New Digital User

Today, we’re focussed on getting to know our new target: she’s online, mobile, and connected to a large network of friends, information, and marketers who help her make decisions about...

Warehousing of HCV patients reaches new high

White Papers and Resources | December 19, 2013 | Inizio

A new study conducted by Research Partnership reveals that 90% of physicians treating HCV patients in the US have reported they are now “warehousing” patients (holding off treatment) in expectation...

Brand leaders in RA will lose market share, predict rheumatologists

White Papers and Resources | December 19, 2013 | Inizio

Rheumatologists believe that the current market for biologic treatments in Rheumatoid Arthritis (RA) will see key changes in the next three years.